Cargando…
Site-Specific Antibody Conjugation for ADC and Beyond
Antibody-drug conjugates (ADCs) have become a promising class of antitumor agents with four conjugates being approved by regulatory agencies for treating cancer patients. To improve the conventional conjugations that are currently applied to generate these heterogeneous products, various site-specif...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744088/ https://www.ncbi.nlm.nih.gov/pubmed/29120405 http://dx.doi.org/10.3390/biomedicines5040064 |